AstraZeneca plc (AZN) Receives Consensus Rating of “Hold” from Brokerages
Shares of AstraZeneca plc (LON:AZN) have earned an average recommendation of “Hold” from the twenty-two ratings firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is GBX 5,124.90 ($67.63).
AZN has been the topic of several research reports. Liberum Capital reissued a “buy” rating and set a GBX 4,800 ($63.34) price objective on shares of AstraZeneca plc in a research note on Tuesday, September 5th. HSBC Holdings plc boosted their price objective on shares of AstraZeneca plc from GBX 4,100 ($54.10) to GBX 4,150 ($54.76) and gave the stock a “reduce” rating in a research note on Monday, October 9th. UBS AG set a GBX 4,550 ($60.04) price objective on shares of AstraZeneca plc and gave the stock a “neutral” rating in a research note on Monday, October 23rd. Jefferies Group LLC boosted their price objective on shares of AstraZeneca plc from GBX 4,350 ($57.40) to GBX 4,800 ($63.34) and gave the stock a “hold” rating in a research note on Monday, September 11th. Finally, Deutsche Bank AG reissued a “buy” rating and set a GBX 5,600 ($73.90) price objective on shares of AstraZeneca plc in a research note on Wednesday, October 11th.
Shares of AstraZeneca plc (LON:AZN) opened at 5022.00 on Friday. The company has a 50 day moving average of GBX 4,991.11 and a 200-day moving average of GBX 4,921.70. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The firm’s market cap is GBX 63.58 billion.
TRADEMARK VIOLATION WARNING: “AstraZeneca plc (AZN) Receives Consensus Rating of “Hold” from Brokerages” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/29/astrazeneca-plc-azn-receives-consensus-rating-of-hold-from-brokerages-2.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.